Health Canada Approves Updated Novavax COVID-19 Vaccine for Fall

The new Nuvaxovid vaccine targets the JN.1 Omicron subvariant and is recommended for high-risk groups.

Health Canada has authorized the updated Novavax COVID-19 vaccine, named Nuvaxovid, for individuals aged 12 and older.
Nuvaxovid has been reformulated to target the JN.1 subvariant of Omicron, replacing the previous version that targeted XBB.1.5.
The National Advisory Committee on Immunization (NACI) strongly recommends the updated vaccine for high-risk groups, including adults 65 and older and those with underlying medical conditions.
Health Canada has also recently approved Moderna's updated mRNA COVID-19 vaccine and is expected to decide on Pfizer's updated vaccine soon.
Provinces and territories have been asked to dispose of older vaccines to ensure the most current formulations are used during this fall's respiratory virus season.